Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Result of venetoclax plus/minus azacitidine for R/R MDS

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing phase 1b, open-label, multicenter study (NCT02966782) evaluating the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in relapsed/refractory myelodysplastic syndromes (MDS). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.